| 1 |
Neurath L, D'Amico F, Danese S. Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials. Expert Opin Emerg Drugs 2023;:1-16. [PMID: 36876333 DOI: 10.1080/14728214.2023.2186399] [Reference Citation Analysis]
|
| 2 |
Hibi T, Motoya S, Hisamatsu T, Hirai F, Watanabe K, Matsuoka K, Saruta M, Kobayashi T, Feagan BG, Tasset C, Besuyen R, Yun C, Crans G, Zhang J, Kondo A, Watanabe M. Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial. Intest Res 2023;21:110-25. [PMID: 35263963 DOI: 10.5217/ir.2021.00143] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 3 |
Wong U, Cross RK. Emerging drugs for the treatment of inflammatory bowel disease. Expert Opin Emerg Drugs 2022;27:369-77. [PMID: 36369862 DOI: 10.1080/14728214.2022.2147507] [Reference Citation Analysis]
|
| 4 |
D'Amico F, Peyrin-Biroulet L, Danese S. Is Selectivity the JAKpot Winner for Inflammatory Bowel Disease Treatment? Gastroenterology 2022;163:1482-4. [PMID: 36155194 DOI: 10.1053/j.gastro.2022.09.011] [Reference Citation Analysis]
|
| 5 |
Mannucci A, D'Amico F, El Saadi A, Peyrin-Biroulet L, Danese S. Filgotinib for moderately to severely active ulcerative colitis. Expert Rev Gastroenterol Hepatol 2022;16:927-40. [PMID: 36278878 DOI: 10.1080/17474124.2022.2138857] [Reference Citation Analysis]
|
| 6 |
Ananthakrishnan AN. Upadacitinib for ulcerative colitis. Lancet 2022;399:2077-8. [PMID: 35644164 DOI: 10.1016/S0140-6736(22)00778-4] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 7 |
Napolitano M, D'Amico F, Ragaini E, Peyrin-Biroulet L, Danese S. Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy. Drug Des Devel Ther 2022;16:1897-913. [PMID: 35747444 DOI: 10.2147/DDDT.S340459] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 9.0] [Reference Citation Analysis]
|
